Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $896.88, giving the company a market capitalization of 93.32B. It carries a P/E multiple of 20.55 and pays a dividend yield of 0.40%.
On 2026-11-06, Regeneron(REGN) stock moved within a range of $896.88 to $948.06. With shares now at $896.88, the stock is trading 0.0% above its intraday low and -5.4% below the session's peak.
Trading activity shows a volume of 1.41M, compared to an average daily volume of 1.15M.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
REGN News
has rallied hard over the past few years, and fresh earnings headlines keep pulling investor attention back to the same issue. With the share price moving quick...
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is testing ALN-CIDEB in adults...
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN Quick QuoteREGN - Free Report) and Ill...
Analyst ratings
65%
of 31 ratingsMore REGN News
Regeneron Pharmaceuticals reported third quarter 2026 revenue of US$5.1158b and net income of US$1.9487b, with basic earnings per share from continuing operatio...
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals (REGN) and Sano...
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF). Citig...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07...
Regeneron Pharmaceuticals ((REGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Regeneron’s latest earnings call struck an empha...
On its third quarter of 2026 earnings call, held on Oct. 30, 2026, Regeneron (REGN +13.33%) reported total revenue of $5.1 billion, representing 36% year-over-y...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock hit a new 52-week high Friday after the biotechnology company reported better-than-expected third-quarter 202...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.